Detalhe da pesquisa
1.
Immune checkpoint therapy-elicited sialylation of IgG antibodies impairs antitumorigenic type I interferon responses in hepatocellular carcinoma.
Immunity
; 56(1): 180-192.e11, 2023 01 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36563676
2.
Targeting inflammatory macrophages rebuilds therapeutic efficacy of DOT1L inhibition in hepatocellular carcinoma.
Mol Ther
; 31(1): 105-118, 2023 01 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36183166